Dacomitinib is a kinase inhibitor used in the treatment of non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic). It is mainly used as a first treatment option if tumors have certain types of abnormal EGFR gene(s).
Dosage: The recommended vizimpro dose is 45 mg administered orally once daily, until the disease is progressive or unacceptable toxicity is noticed. It can be administered either with or without food. Take dacomitinib tablets at the same time each day. If the patient pukes or misses any particular dose, do not administer an additional dose or make up a missed dose but must continue with the next scheduled dose.
Side Effects: The most commonly reported dacomitinib side effects may include:
- Common cold
- Dry skin
- Dry, red, itchy eyes
- Hair loss
- Nail inflammation
- Decreased appetite
- Decreased weight
- Mouth pain and sores
Warnings and Precautions:
- Patients with dacomitinib tablets should be monitored for pulmonary symptoms indicative of pneumonitis or ILD.
- Patients with the therapy of vizimpro 45 mg are advised to contact their doctor if they notice first signs of diarrhea. Patients are advised that intravenous hydration or anti-diarrheal drug may be needed to manage diarrhea.
- Verify the pregnancy status of women of reproductive potential before initiating treating with vizimpro 30 mg. As this drug can cause fetal harm if administered to a pregnant woman.
- Females of reproductive potential are advised to use effective contraception while therapy with dacomitinib 15 mg and for at least 17 days following the final dose. Advise women not to breastfeed while on treatment with vizimpro 15 mg and for 17 days following the last dose